Liquid chromatographic determination of enrofloxacin in nasal secretions and plasma of healthy pigs using restricted access material for on-line sample clean-up

被引:29
作者
Bimazubute, M. A. [2 ]
Rozet, E. [3 ]
Dizier, I. [2 ]
Gustin, P. [2 ]
Hubert, Ph. [3 ]
Crommen, J. [4 ]
Chiap, P. [1 ]
机构
[1] Univ Liege, Ctr Hosp, Adv Technol Corp, B-4000 Liege, Belgium
[2] Univ Liege, Fac Vet Med, Dept Funct Sci, Unit Pharmacol Pharmacotherapy & Toxicol, B-4000 Liege, Belgium
[3] Univ Liege, Bioanalyt Chem Res Unit, Analyt Chem Lab, B-4000 Liege, Belgium
[4] Univ Liege, Bioanalyt Chem Res Unit, Dept Pharmaceut Analyt Chem, B-4000 Liege, Belgium
关键词
enrofloxacin; nasal secretions; plasma; restricted access material; column-switching; healthy pigs; validation;
D O I
10.1016/j.chroma.2007.11.011
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new fully automated method was developed for the quantitative analysis of an antibacterial drug, enrofloxacin (ENRO), in both nasal secretions and plasma samples of healthy pigs. The method is based on the use of a pre-column packed with restricted access material (RAM), namely R-P-18 ADS (alkyl diol silica), for on-line sample clean-up coupled to a liquid chromatographic (LC) column containing octadecyl silica. The only off-line sample preparation was the 50-fold dilution of nasal secretions and plasma samples in the washing liquid composed of 25 mM phosphate buffer of pH 7.4. A 10 mu l diluted sample volume was injected directly onto the pre-column and washed for 7 min. By rotation of a switching valve, the analyte of interest was eluted in the back-flush mode with the LC mobile phase which consisted in a mixture of 25 mM phosphate buffer of pH 3.0 and acetonitrile according to a segmented gradient elution. By a new rotation of the switching valve, the pre-column and the analytical column were equilibrated for 3 min with the initial mobile phases. The flow-rate was 0.8 ml min(-1) for the washing liquid and 1.5 ml min(-1) for the LC mobile phase. ENRO was detected by fluorescence at excitation and emission wavelengths of 278 and 445 nm, respectively. Finally, the developed method was validated using an original strategy based on total measurement error and accuracy profiles as a decision tool. The limits of quantitation of ENRO in plasma and in nasal secretions were 30.5 and 91.6 ng/ml, respectively. The validated method was then applied successfully to the determination of ENRO in healthy pigs treated by intramuscular injection at different doses (2.5, 10 and 30 mg/kg bodyweight) for a pilot study. This method could be also used for the simultaneous analysis of ENRO and its main metabolite, ciprofloxacin (CIPRO). (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:456 / 466
页数:11
相关论文
共 41 条
[11]   Fully automated method for the liquid chromatographic-tandem mass spectrometric determination of cyproterone acetate in human plasma using restricted access material for on-line sample clean-up [J].
Christiaens, B ;
Fillet, A ;
Chiap, P ;
Rbeida, O ;
Ceccato, A ;
Streel, B ;
De Graeve, J ;
Crommen, J ;
Hubert, P .
JOURNAL OF CHROMATOGRAPHY A, 2004, 1056 (1-2) :105-110
[12]  
*EA, 2004, 416 EA
[13]  
EURACHEM/CITAC Guideline, 2000, QUANT UNC AN MEAS, V2nd edition
[14]  
*FDA, 2004, PROC AN TECHN IN
[15]   New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data [J].
Feinberg, M ;
Boulanger, B ;
Dewé, W ;
Hubert, P .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2004, 380 (03) :502-514
[16]   Determination of fluoroquinolones in serum using an on-line clean-up column coupled to high-performance immunoaffinity-reversed-phase liquid chromatography [J].
Holtzapple, CK ;
Buckley, SA ;
Stanker, LH .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2001, 754 (01) :1-9
[17]   Harmonization of strategies for the validation of quantitative analytical procedures -: A SFSTP proposal -: part I [J].
Hubert, P ;
Nguyen-Huu, JJ ;
Boulanger, B ;
Chapuzet, E ;
Chiap, P ;
Cohen, N ;
Compagnon, PA ;
Dewé, W ;
Feinberg, M ;
Lallier, M ;
Laurentie, M ;
Mercier, N ;
Muzard, G ;
Nivet, C ;
Valat, L .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 36 (03) :579-586
[18]  
HUBERT P, 2006, STP PHARM PRATIQUES, V16, P28
[19]  
Hubert P., 2003, STP Pharma Prat Tech Reglementations, V13, P101
[20]  
*INT C HARM, 2005, QUAL RISK MAN Q9